Editas Medicine (EDIT) Misses Q2 EPS by 15c

Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.82), $0.15 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $6.73 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Venture Global exports 127 LNG cargos in Q2 2026
• Honeywell Technologies revises 2026 EPS guidance after stock split